OPKO Health Inc. (OPK) stock soared 7.36% in pre-market trading on Friday, following its impressive fourth-quarter 2024 financial results and promising advancements in its pharmaceutical pipeline.
The biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for Q4 2024, a remarkable turnaround from a net loss of $66.5 million in the same period last year. This positive performance was driven by:
OPKO's pharmaceutical pipeline made notable strides, with its tetraspecific antibody (MDX-2001) for solid tumors and the EBV nanoparticle vaccine in collaboration with Merck entering Phase 1 clinical trials. The company also reported encouraging clinical pharmacology data for its once-weekly injectable dual-GLP-1 glucagon agonist (OPKO-88006) in diabetic and metabolic mice models.
Furthermore, OPKO strengthened its financial position through various transactions, including the infusion of cash from the Merck collaboration and the sale of GeneDx. This allowed the company to fund its pipeline advancement and initiate share buybacks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.